Investment Thesis
UnitedHealth demonstrates strong top-line expansion at 11.8%, but this is severely undermined by a 16.3% net income decline, revealing critical margin compression across the business. While positive free cash flow ($8.1B) and manageable leverage (9.4x interest coverage) provide some stability, deteriorating profitability, weak returns (6.0% ROE, 2.0% ROA), and working capital stress (0.80x current ratio) indicate operational challenges that must be resolved.
Strengths
- Strong revenue growth of 11.8% year-over-year demonstrates solid market demand in healthcare services
- Robust free cash flow generation of $8.1B and manageable debt/equity ratio of 0.69x provides financial flexibility
- Strong interest coverage ratio of 9.4x and substantial cash reserves of $28.0B enable operational stability
Risks
- Net income declined 16.3% YoY despite revenue growth, indicating severe profit margin compression and cost control issues
- Current ratio of 0.80x and quick ratio of 0.77x below 1.0x suggest working capital management concerns and liquidity stress
- Weak return metrics (6.0% ROE, 2.0% ROA) indicate poor capital efficiency and value creation for shareholders
Key Metrics to Watch
- Net income and operating margin trends—critical to determine if profitability decline reverses
- Current and quick ratios—must improve above 1.0x to signal resolution of working capital issues
- Operating expenses as percentage of revenue—will reveal whether cost inflation is being controlled
Financial Metrics
Revenue
111.7B
Net Income
6.3B
EPS (Diluted)
$6.90
Free Cash Flow
8.1B
Total Assets
312.6B
Cash
28.0B
Profitability Ratios
Gross Margin
N/A
Operating Margin
8.0%
Net Margin
5.6%
ROE
6.0%
ROA
2.0%
FCF Margin
7.3%
Balance Sheet & Liquidity
Current Ratio
0.80x
Quick Ratio
0.77x
Debt/Equity
0.69x
Debt/Assets
66.3%
Interest Coverage
9.41x
Long-term Debt
71.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T11:09:37.113063 |
Data as of: 2026-03-31 |
Powered by Claude AI